IR News 2017


March 24, 2017 Corporate

Nippon Shinyaku enters into a license agreement with Delta-Fly Pharma on DFP-10917, a therapeutic agent for relapsed/refractory acute myeloid leukemia

Nippon Shinyaku Co., Ltd. (HQ: Kyoto, President: Shigenobu Maekawa) and Delta-Fly Pharma, Inc. (HQ: Tokushima, Japan, President: Kiyoshi Eshima) announced that the two companies have signed a license agreement on DFP-10917 for the treatment of relapsed/refractory (r/r) acute myeloid leukemia (AML). This agreement enables Nippon Shinyaku to exclusively develop and commercialize DFP-10917 in Japan.


DFP-10917 is a novel deoxycytidine analog that induces DNA damage by the different mechanism of action from other nucleoside analogs. Delta-Fly Pharma, Inc. has completed a phase 1/2 clinical study of DFP-10917 for r/r AML initiated at The University of Texas MD Anderson Cancer Center in the US.


In the study, DFP-10917 demonstrated a significant anti-leukemic activity with tolerable safety profile in r/r AML by low dose continuous infusion. On the basis of the result, a global phase 3 clinical study is planned in 2017.


DFP-10917 is expected to fulfill an unmet medical need in the treatment of r/r AML. Nippon Shinyaku aims to contribute to improving treatment for elderly patients with r/r AML by launching DFP-10917 in Japan as soon as possible.




Delta-Fry Pharma, Inc. is a privately held bio-pharmaceutical company established in 2010 with headquarters in Tokushima, Japan. The company is engaged in the research and development of drugs for the treatment of cancer.